CNS Drugs

, Volume 27, Issue 12, pp 1007–1019 | Cite as

Novel Delivery Systems for Nicotine Replacement Therapy as an Aid to Smoking Cessation and for Harm Reduction: Rationale, and Evidence for Advantages over Existing Systems

  • Lion ShahabEmail author
  • Leonie S. Brose
  • Robert West
Leading Article


Nicotine replacement therapy (NRT) has been used in the treatment of tobacco dependence for over three decades. Whilst the choice of NRT was limited early on, in the last ten years there has been substantial increase in the number of nicotine delivery devices that have become available. This article briefly summarises existing forms of NRT, evidence of their efficacy and use, and reviews the rationale for the development of novel products delivering nicotine via buccal, transdermal or pulmonary routes (including nicotine mouth spray, nicotine films, advanced nicotine inhalers and electronic cigarettes). It presents available evidence on the efficacy, tolerability and abuse potential of these products, with a focus on their advantages as well as disadvantages compared with established forms of NRT for use as an aid to both smoking cessation as well as harm reduction.


Nicotine Smoking Cessation Nicotine Replacement Therapy Harm Reduction Tobacco User 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Disclosures and acknowledgments

No source of funding was used to assist with the preparation of this manuscript. LSB has no competing interests. LS has received honoraria for talk and travel expenses from manufacturers of medications for smoking cessation to attend meetings and workshops. RW has undertaken research and consultancy for companies that develop and manufacture smoking cessation medications. He also has a share of a patent in a novel nicotine delivery device (the nicotine cannon) and received royalties for books on addiction and smoking.


  1. 1.
    Shafey O, Eriksen M, Ross H, Mackay J. The tobacco atlas. 3rd ed. Atlanta: American Cancer Society; 2009.Google Scholar
  2. 2.
    Waldum HL, Nilsen OG, Nilsen T, Rorvik H, Syversen V, Sanvik AK, et al. Long-term effects of inhaled nicotine. Life Sci. 1996;58:1339–46.PubMedGoogle Scholar
  3. 3.
    Sumner W. Estimating the health consequences of replacing cigarettes with nicotine inhalers. Tob Control. 2003;12:124–32.PubMedGoogle Scholar
  4. 4.
    Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend. 1993;33:23–9.PubMedGoogle Scholar
  5. 5.
    Jarvis MJ. Why people smoke. BMJ. 2004;328:277–9.PubMedGoogle Scholar
  6. 6.
    Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron. 1998;21:467–76.PubMedGoogle Scholar
  7. 7.
    Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res. 2000;2:19–37.PubMedGoogle Scholar
  8. 8.
    Centers for Disease Control and Prevention. The health consequences of smoking: nicotine addiction. A report of the surgeon general. Rockville: US Department of Health and Human Services; 1988.Google Scholar
  9. 9.
    Royal College of Physicians. Nicotine addiction in Britain. A report of the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians of London; 2000.Google Scholar
  10. 10.
    West R. The multiple facets of cigarette addiction and what they mean for encouraging and helping smokers to stop. COPD. 2009;6:277–83.PubMedGoogle Scholar
  11. 11.
    International Agency for Research on Cancer. Tobacco smoke and involuntary smoking. In: IARC monographs on the evaluation of carcinogenic risks to humans, vol 83. Lyon: IARC; 2004. p. 973–991.Google Scholar
  12. 12.
    Press release: UK moves towards safe and effective electronic cigarettes and other nicotine-containing products. MHRA website.
  13. 13.
    Johnston L. Tobacco smoking and nicotine. Lancet. 1942;240:742.Google Scholar
  14. 14.
    Herxheimer A, Griffith R, Hamilton B, Wakefield M. Circulatory effects of nicotine aerosol inhalations and cigarette smoking in man. Lancet. 1967;290:754–5.Google Scholar
  15. 15.
    Ferno O. Conversation with Ove Ferno. Addiction. 1994;89:1215–26.PubMedGoogle Scholar
  16. 16.
    West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med. 2011;365:1193–200.PubMedGoogle Scholar
  17. 17.
    Mees HL, Keutzer CS, Lichtenstein E. Modification of smoking behavior: a review. Psychol Bull. 1968;70:520–33.PubMedGoogle Scholar
  18. 18.
    Ferno O, Lichtnec SJ, Lundgren CE. Substitute for tobacco smoking. Psychopharmacologia. 1973;31:201–4.PubMedGoogle Scholar
  19. 19.
    Brantmark B, Ohlin P, Westling H. Nicotine-containing chewing gum as an anti-smoking aid. Psychopharmacologia. 1973;31:191–200.PubMedGoogle Scholar
  20. 20.
    Jarvik M. Conversation with Murray Jarvik. Addiction. 2001;96:1241–52.PubMedGoogle Scholar
  21. 21.
    Buchhalter AR, Fant RV, Henningfield JE. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs. 2008;68:1067–88.PubMedGoogle Scholar
  22. 22.
    Rose JE, Herskovic JE, Trilling Y, Jarvik ME. Transdermal nicotine reduces cigarette craving and nicotine preference. Clin Pharmacol Ther. 1985;38:450–6.PubMedGoogle Scholar
  23. 23.
    Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.Google Scholar
  24. 24.
    Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med. 1999;159:2033–8.PubMedGoogle Scholar
  25. 25.
    Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE, et al. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res. 1999;1:169–74.PubMedGoogle Scholar
  26. 26.
    Sutherland G, Stapleton JA, Russell MA, Jarvis MJ, Hajek P, Belcher M, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet. 1992;340:324–9.PubMedGoogle Scholar
  27. 27.
    Fagerstrom KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology (Berl). 1993;111:271–7.Google Scholar
  28. 28.
    Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med. 1995;24:41–7.PubMedGoogle Scholar
  29. 29.
    Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009;66:1253–62.PubMedGoogle Scholar
  30. 30.
    Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;CD000146.Google Scholar
  31. 31.
    Walsh RA. Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness. Drug Alcohol Rev. 2008;27:529–47.PubMedGoogle Scholar
  32. 32.
    Comparison of four methods of smoking withdrawal in patients with smoking related diseases. Report by a subcommittee of the Research Committee of the British Thoracic Society. Br Med J (Clin Res Ed). 1983;286:595–7.Google Scholar
  33. 33.
    Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA. 2002;288:1260–4.PubMedGoogle Scholar
  34. 34.
    Foulds J, Steinberg MB, Williams JM, Ziedonis DM. Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug Alcohol Rev. 2006;25:59–71.PubMedGoogle Scholar
  35. 35.
    Parrott S, Godfrey C, Raw M, West R, McNeill A. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority. Thorax. 1998;53(Suppl 5 Pt 2):S1–38.PubMedGoogle Scholar
  36. 36.
    Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess. 2002;6:1–245.Google Scholar
  37. 37.
    Stapleton JA, Lowin A, Russell MA. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet. 1999;354:210–5.PubMedGoogle Scholar
  38. 38.
    Akehurst R, Piercy J. Cost-effectiveness of the use of transdermal Nicorette patches relative to GP counselling and nicotine gum in the prevention of smoking related diseases. Br J Med Econ. 1994;7:115–22.Google Scholar
  39. 39.
    Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. 1997;278:1759–66.PubMedGoogle Scholar
  40. 40.
    Appleby J, Devlin N, Parkin D. NICE’s cost effectiveness threshold. BMJ. 2007;335:358–9.PubMedGoogle Scholar
  41. 41.
    NICE. Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities. In: NICE public health guidance 10. London: National Institute for Health and Clinical Excellence; 2008.Google Scholar
  42. 42.
    West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax. 2000;55:987–99.PubMedGoogle Scholar
  43. 43.
    USDHHS. Clinical practical guidelines. In: Treating tobacco use and dependence—2008 update. Rockville: US Department of Health and Human Services P.H.S.; 2008.Google Scholar
  44. 44.
    Hughes JR, Shiffman S, Callas P, Zhang J. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control. 2003;12:21–7.PubMedGoogle Scholar
  45. 45.
    Raw M, Regan S, Rigotti NA, McNeill A. A survey of tobacco dependence treatment services in 36 countries. Addiction. 2009;104:279–87.PubMedGoogle Scholar
  46. 46.
    WHO Tobacco Free Initiative. Policy recommendations for smoking cessation and treatment of tobacco dependence. Geneva: WHO; 2003.Google Scholar
  47. 47.
    Hughes JR, Hatsukami DK, Pickens RW, Krahn D, Malin S, Luknic A. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology (Berl). 1984;83:82–7.Google Scholar
  48. 48.
    West R, Jarvis MJ, Russell MA, Carruthers ME, Feyerabend C. Effect of nicotine replacement on the cigarette withdrawal syndrome. Br J Addict. 1984;79:215–9.PubMedGoogle Scholar
  49. 49.
    Jarvis MJ, Raw M, Russell MA, Feyerabend C. Randomised controlled trial of nicotine chewing-gum. Br Med J (Clin Res Ed). 1982;285:537–40.Google Scholar
  50. 50.
    West R. The ‘nicotine replacement paradox’ in smoking cessation: how does nicotine gum really work? Br J Addict. 1992;87:165–7.PubMedGoogle Scholar
  51. 51.
    Shiffman S, Fant RV, Buchhalter AR, Gitchell JG, Henningfield JE. Nicotine delivery systems. Expert Opin Drug Deliv. 2005;2:563–77.PubMedGoogle Scholar
  52. 52.
    Esterlis I, Mitsis EM, Batis JC, Bois F, Picciotto MR, Stiklus SM, et al. Brain beta2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. Int J Neuropsychopharmacol. 2011;14:389–98.PubMedGoogle Scholar
  53. 53.
    West R, Shiffman S. Fast facts: smoking cessation. 2nd ed. Oxford: Health Press; 2007.Google Scholar
  54. 54.
    Beard E, McNeill A, Aveyard P, Fidler J, Michie S, West R. Association between use of nicotine replacement therapy for harm reduction and smoking cessation: a prospective study of English smokers. Tob Control. 2013;22:118–22.PubMedGoogle Scholar
  55. 55.
    Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ. 2009;338:b1024.PubMedGoogle Scholar
  56. 56.
    Agboola S, McNeill A, Coleman T, Leonardi BJ. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction. 2010;105:1362–80.PubMedGoogle Scholar
  57. 57.
    Raw M, McNeill A, West R, Arnott D. Guidance for health professionals on changes in the licensing arrangements for nicotine replacement therapy. London: ASH; 2005.Google Scholar
  58. 58.
    Henningfield JE, Slade J. Tobacco-dependence medications: public health and regulatory issues. Food Drug Law J. 1998;53(suppl):75–114.PubMedGoogle Scholar
  59. 59.
    Schneider NG, Koury MA, Cortner C, Olmstead RE, Hartman N, Kleinman L, et al. Preferences among four combination nicotine treatments. Psychopharmacology (Berl). 2006;187:476–85.Google Scholar
  60. 60.
    Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med. 2004;140:426–33.PubMedGoogle Scholar
  61. 61.
    West R, DiMarino ME, Gitchell J, McNeill A. Impact of UK policy initiatives on use of medicines to aid smoking cessation. Tob Control. 2005;14:166–71.PubMedGoogle Scholar
  62. 62.
    Kotz D, Fidler JA, West R. Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications? Nicotine Tob Res. 2011;13:793–9.PubMedGoogle Scholar
  63. 63.
    Pomerleau OF. Nicotine and the central nervous system: biobehavioral effects of cigarette smoking. Am J Med. 1992;93:2S–7S.PubMedGoogle Scholar
  64. 64.
    Russell MA, Sutton SR, Iyer R, Feyerabend C, Vesey CJ. Long-term switching to low-tar low-nicotine cigarettes. Br J Addict. 1982;77:145–58.PubMedGoogle Scholar
  65. 65.
    McRobbie H, Raw M, Chan S. Research priorities for Article 14—demand reduction measures concerning tobacco dependence and cessation. Nicotine Tob Res. 2013;15:805–16.PubMedGoogle Scholar
  66. 66.
    DeVeaugh-Geiss AM, Chen LH, Kotler ML, Ramsay LR, Durcan MJ. Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers. Clin Ther. 2010;32:1140–8.PubMedGoogle Scholar
  67. 67.
    Shiffman S, Ferguson SG, Gwaltney CJ, Balabanis MH, Shadel WG. Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. Psychopharmacology (Berl). 2006;184:637–44.Google Scholar
  68. 68.
    Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J. 1999;13:238–46.PubMedGoogle Scholar
  69. 69.
    Chen L-L, Inventors. United States Patent Application Publication (US 20011/0110880 A1). Nicotine Lozenge compositions (Application number: 12/990,049, filed 30 Apr 2009). 2011.Google Scholar
  70. 70.
    MHRA. Public assessment report. Nicabate Mini 1.5 mg compressed lozenges and Nicabate Mini 4 mg compressed lozenges. Accessed online June 2013.
  71. 71.
    Shahab L, McEwen A, West R. Acceptability and effectiveness for withdrawal symptom relief of a novel oral nicotine delivery device: a randomised crossover trial. Psychopharmacology (Berl). 2011;216:187–96.Google Scholar
  72. 72.
    Niaura R, Sayette M, Shiffman S, Glover ED, Nides M, Shelanski M, et al. Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction. 2005;100:1720–30.PubMedGoogle Scholar
  73. 73.
    Shiffman S, Cone EJ, Buchhalter AR, Henningfield JE, Rohay JM, Gitchell JG, et al. Rapid absorption of nicotine from new nicotine gum formulations. Pharmacol Biochem Behav. 2009;91:380–4.PubMedGoogle Scholar
  74. 74.
    McEwen A, West R, Gaiger M. Nicotine absorption from seven current nicotine replacement products and a new wide-bore nicotine delivery device. J Smok Cessat. 2008;3:117–23.Google Scholar
  75. 75.
    Bolliger CT, van Biljon X, Axelsson A. A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy. Respiration. 2007;74:196–201.PubMedGoogle Scholar
  76. 76.
    Kraiczi H, Hansson A, Perfekt R. Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy. Nicotine Tob Res. 2011;13:1176–82.PubMedGoogle Scholar
  77. 77.
    McRobbie H, Thornley S, Bullen C, Lin RB, Senior H, Laugesen M, et al. A randomized trial of the effects of two novel nicotine replacement therapies on tobacco withdrawal symptoms and user satisfaction. Addiction. 2010;105:1290–8.PubMedGoogle Scholar
  78. 78.
    Hansson A, Hajek P, Perfekt R, Kraiczi H. Effects of nicotine mouth spray on urges to smoke, a randomised clinical trial. BMJ Open. 2012;2:e001618.Google Scholar
  79. 79.
    Tonnesen P, Lauri H, Perfekt R, Mann K, Batra A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. Eur Respir J. 2012;40:548–54.PubMedGoogle Scholar
  80. 80.
    Thornley S, McRobbie H, Lin RB, Bullen C, Hajek P, Laugesen M, et al. A single-blind, randomized, crossover trial of the effects of a nicotine pouch on the relief of tobacco withdrawal symptoms and user satisfaction. Nicotine Tob Res. 2009;11:715–21.PubMedGoogle Scholar
  81. 81.
    Walker N, Howe C, Bullen C, Grigg M, Glover M, McRobbie H, et al. Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomized controlled trial. Addiction. 2011;106:1176–85.PubMedGoogle Scholar
  82. 82.
    Caldwell B, Burgess C, Crane J. Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers. Nicotine Tob Res. 2010;12:179–83.PubMedGoogle Scholar
  83. 83.
    GlaxoSmithKline. Clinical Trial: Nicotine Mouth Film for Craving Relief (NCT01702532). 2013.
  84. 84.
    Cilurzo F, Cupone IE, Minghetti P, Buratti S, Selmin F, Gennari CG, et al. Nicotine fast dissolving films made of maltodextrins: a feasibility study. AAPS PharmSciTech. 2010;11:1511–7.PubMedGoogle Scholar
  85. 85.
    MHRA. Public assessment report: Nicabate mint 2.5 mg orodispersable film (PL 00079/0640). Accessed online June 2013.
  86. 86.
    Valenta C, Auner BG. The use of polymers for dermal and transdermal delivery. Eur J Pharm Biopharm. 2004;58:279–89.PubMedGoogle Scholar
  87. 87.
    Pichayakorn W, Suksaeree J, Boonme P, Amnuaikit T, Taweepreda W, Ritthidej GC. Deproteinized natural rubber film forming polymeric solutions for nicotine transdermal delivery. Pharm Dev Technol. 2013;18:1111–21.PubMedGoogle Scholar
  88. 88.
    Rao S, Song Y, Peddie F, Evans AM. A novel tri-layered buccal mucoadhesive patch for drug delivery: assessment of nicotine delivery. J Pharm Pharmacol. 2011;63:794–9.PubMedGoogle Scholar
  89. 89.
    Strasinger CL, Scheff NN, Wu J, Hinds BJ, Stinchcomb AL. Carbon nanotube membranes for use in the transdermal treatment of nicotine addiction and opioid withdrawal symptoms. Subst Abuse. 2009;3:31–9.PubMedGoogle Scholar
  90. 90.
    Paudel KS, Wu J, Hinds BJ, Stinchcomb AL. Programmable transdermal delivery of nicotine in hairless guinea pigs using carbon nanotube membrane pumps. J Pharm Sci. 2012;101:3823–32.PubMedGoogle Scholar
  91. 91.
    Wu J, Paudel KS, Strasinger C, Hammell D, Stinchcomb AL, Hinds BJ. Programmable transdermal drug delivery of nicotine using carbon nanotube membranes. Proc Natl Acad Sci USA. 2010;107:11698–702.PubMedGoogle Scholar
  92. 92.
    D’Orlando KJ, Fox BS. Tolerability and pharmacokinetics of single and repeated doses of nicotine with the straw, a novel nicotine replacement product. Nicotine Tob Res. 2004;6:63–70.PubMedGoogle Scholar
  93. 93.
    Westman EC, Tomlin KF, Perkins CE, Rose JE. Oral nicotine solution for smoking cessation: a pilot tolerability study. Nicotine Tob Res. 2001;3:391–6.PubMedGoogle Scholar
  94. 94.
    Henningfield JE, Radzius A, Cooper TM, Clayton RR. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum. JAMA. 1990;264:1560–4.PubMedGoogle Scholar
  95. 95.
    Islam N, Rahman S. Improved treatment of nicotine addiction and emerging pulmonary drug delivery. Drug Discov Ther. 2012;6:123–32.PubMedGoogle Scholar
  96. 96.
    Caldwell B, Sumner W, Crane J. A systematic review of nicotine by inhalation: is there a role for the inhaled route? Nicotine Tob Res. 2012;14:1127–39.PubMedGoogle Scholar
  97. 97.
    Lux JE, Frecker RC. Subjective responses to inhaled and intravenous injected nicotine. Clin Pharmacol Ther. 1988;43:186.Google Scholar
  98. 98.
    Burch SG, Erbland ML, Gann LP, Hiller FC. Plasma nicotine levels after inhalation of aerosolized nicotine. Am Rev Respir Dis. 1989;140:955–7.PubMedGoogle Scholar
  99. 99.
    Andrus PG, Rhem R, Rosenfeld J, Dolovich MB. Nicotine microaerosol inhaler. Can Respir J. 1999;6:509–12.PubMedGoogle Scholar
  100. 100.
    Caldwell B, Dickson S, Burgess C, Siebers R, Mala S, Parkes A, et al. A pilot study of nicotine delivery to smokers from a metered-dose inhaler. Nicotine Tob Res. 2009;11:342–7.PubMedGoogle Scholar
  101. 101.
    Farr SJ, Warren SJ, Lloyd P, Okikawa JK, Schuster JA, Rowe AM, et al. Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler. Int J Pharm. 2000;198:63–70.PubMedGoogle Scholar
  102. 102.
    Rose JE, Turner JE, Murugesan T, Behm FM, Laugesen M. Pulmonary delivery of nicotine pyruvate: sensory and pharmacokinetic characteristics. Exp Clin Psychopharmacol. 2010;18:385–94.PubMedGoogle Scholar
  103. 103.
    Wollscheid KA, Kremzner ME. Electronic cigarettes: safety concerns and regulatory issues. Am J Health Syst Pharm. 2009;66:1740–2.PubMedGoogle Scholar
  104. 104.
    Goniewicz ML, Kuma T, Gawron M, Knysak J, Kosmider L. Nicotine levels in electronic cigarettes. Nicotine Tob Res. 2013;15:158–66.PubMedGoogle Scholar
  105. 105.
    Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control. 2010;19:98–103.PubMedGoogle Scholar
  106. 106.
    Vansickel AR, Cobb CO, Weaver MF, Eissenberg TE. A clinical laboratory model for evaluating the acute effects of electronic “cigarettes”: nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomarkers Prev. 2010;19:1945–53.PubMedGoogle Scholar
  107. 107.
    Vansickel AR, Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res. 2013;15:267–70.PubMedGoogle Scholar
  108. 108.
    Dawkins L, Turner J, Hasna S, Soar K. The electronic-cigarette: effects on desire to smoke, withdrawal symptoms and cognition. Addict Behav. 2012;37:970–3.PubMedGoogle Scholar
  109. 109.
    Bullen C, Williman J, Howe C, Laugesen M, McRobbie H, Parag V, et al. Study protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation. BMC Public Health. 2013;13:210.PubMedGoogle Scholar
  110. 110.
    Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, et al. Efficiency and safety of an electronic cigarette (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2013;8:e66317.PubMedGoogle Scholar
  111. 111.
    Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet (In press).Google Scholar
  112. 112.
    Polosa R, Morjaria JB, Caponnetto P, Campagna D, Russo C, Alamo A, et al. Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Intern Emerg Med. 2013. doi: 10.1007/s11739-013-0977-z.
  113. 113.
    Caponnetto P, Auditore R, Russo C, Cappello GC, Polosa R. Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. Int J Environ Res Public Health. 2013;10:446–61.PubMedGoogle Scholar
  114. 114.
    Trehy ML, Ye W, Hadwiger ME, Moore TW, Allgire JF, Woodruff JT, et al. Analysis of electronic cigarette cartridges, refill solutions, and smoke for nicotine and nicotine related impurities. J Liquid Chromatogr Relat Technol. 2011;34:1442–58.Google Scholar
  115. 115.
    Hajek P. Withdrawal-oriented therapy for smokers. Br J Addict. 1989;84:591–8.PubMedGoogle Scholar
  116. 116.
    Hurt RD, Dale LC, McClain FL, Eberman KM, Offord KP, Bruce BK, et al. A comprehensive model for the treatment of nicotine dependence in a medical setting. Med Clin North Am. 1992;76:495–514.PubMedGoogle Scholar
  117. 117.
    Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2012;10:CD008286.Google Scholar
  118. 118.
    Sutherland G. Evidence for counselling effectiveness for smoking cessation. J Clin Psychiatry Monogr. 2003;18:22–34.Google Scholar
  119. 119.
    Shahab L, Fidler J. Tobacco-related disorders. In: Sturmey P, Hersen M, editors. Handbook of evidence-based practice in clinical psychology: adult disorders, vol. II. New York: Wiley; 2012. pp. 167–96.Google Scholar
  120. 120.
    McEwen A, Hajek P, McRobbie H, West R. Manual of smoking cessation. Oxford: Blackwell Publishing; 2006.Google Scholar
  121. 121.
    Shahab L. Cost-effectiveness of pharmacotherapy for smoking cessation (NCSCT Briefing: 7). In: McEwen A, editor. NHS Centre for Smoking Cessation and Training Briefings. London: NCSCT; 2011.Google Scholar
  122. 122.
    Fidler JA, Shahab L, West O, Jarvis MJ, McEwen A, Stapleton JA, et al. ‘The smoking toolkit study’: a national study of smoking and smoking cessation in England. BMC Public Health. 2011;11:479.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Department of Epidemiology and Public HealthUniversity College LondonLondonUK
  2. 2.Institute of PsychiatryKing’s College LondonLondonUK

Personalised recommendations